These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 26810276

  • 1. Vedolizumab in the treatment of Crohn's disease.
    Tarabar D, Hirsch A, Rubin DT.
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):283-90. PubMed ID: 26810276
    [Abstract] [Full Text] [Related]

  • 2. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S.
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S, Dignass AU, Hartmann H, Kruis W, Rogler G, Siegmund B, Stallmach A, Witte C, Bokemeyer B.
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [Abstract] [Full Text] [Related]

  • 7. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
    Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G.
    Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP, Cross RK.
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [Abstract] [Full Text] [Related]

  • 9. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP, Domènech E.
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [Abstract] [Full Text] [Related]

  • 10. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK, Shows DM, Chiorean MV, Lord JD.
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [Abstract] [Full Text] [Related]

  • 11. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
    Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K.
    Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
    McLean LP, Cross RK.
    Expert Opin Investig Drugs; 2016 Jan; 25(3):263-73. PubMed ID: 26822204
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R, Ma C, Jairath V, Khanna R, Feagan BG.
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
    Scribano ML.
    World J Gastroenterol; 2018 Jun 21; 24(23):2457-2467. PubMed ID: 29930467
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M.
    Clin Gastroenterol Hepatol; 2017 Feb 21; 15(2):229-239.e5. PubMed ID: 27639327
    [Abstract] [Full Text] [Related]

  • 19. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.
    Aliment Pharmacol Ther; 2016 Dec 21; 44(11-12):1199-1212. PubMed ID: 27714831
    [Abstract] [Full Text] [Related]

  • 20. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M, Cross RK.
    Expert Opin Drug Saf; 2015 Dec 21; 14(9):1473-9. PubMed ID: 26138111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.